Sign up
Pharma Capital
Market: AIM
52-week High/Low: 6.02p / 2.61p
Sector: Pharma & Biotech
Market Cap: 11.05M

Proteome Sciences plc is engaged in the research and development, primarily in the field of proteomics, using techniques to detect and characterize proteins in diseases for diagnostic, prognostic and therapeutic applications. The Company has research facilities in London, United Kingdom and Frankfurt, Germany. Through its ProteoSHOP toolkit, Proteome Sciences Plc provides proteomics solutions, including two dimensional gel-based electrophoresis (2DE) and gel-free protein sequence tag technologies (PST, qPST and TMT), to pharma, biotechnology and diagnostic companies. The Company has an interest of 42.69% in Intronn Inc., an associate company. On September 21, 2007, the Company announced that VIRxSYS Corporation has acquired the core technology and assets of Intronn Inc.

Proteome Sciences is traded in the ISDX Exchange HERE

Proteome Sciences plc

Interactive graph

col 3
col 4
col 5
col 6

Proteome Sciences plc Timeline

View All

Market Reports Including PRM


© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.